TuHURA Biosciences Secures Key U.S. Patent for Delta Opioid Receptor Technology
TuHURA Biosciences has received a U.S. patent for its Delta Opioid Receptor (DOR) antibody drug conjugate (ADC) technology. The patent also covers applications in cellular immunotherapies.
TuHURA Biosciences announced it has been granted a key U.S. patent from the United States Patent and Trademark Office (USPTO) for its Delta Opioid Receptor (DOR) antibody drug conjugate (ADC) technology. The patent, issued on October 5, 2026, strengthens the company's intellectual property in the immuno-oncology space.
The DOR is a protein believed to play a significant role in the growth and progression of certain cancers. TuHURA's technology targets this receptor to develop novel therapeutic approaches for cancer treatment.
Beyond its application in ADCs, the granted patent also broadly covers the utilization of the DOR in autologous or allogeneic adoptive cellular immunotherapies. These include CAR-T, Treg, or TIL cell therapies, which represent emerging modalities in cancer treatment.
TuHURA Biosciences is a Phase 3 immuno-oncology company focused on developing new treatments for challenging cancers. The company aims to improve patient outcomes and quality of life through its pipeline of targeted therapies.
The patent's issuance marks a significant milestone for TuHURA, reinforcing its technological foundation and supporting its ongoing research and development efforts in the pursuit of effective cancer therapies.